Objective To explore the effect of pembrolizumab for the treatment of patients with non⁃small cell lung cancer with brain metastasis of driver gene⁃negative. Methods A total of 140 patients with non⁃small cell lung cancer with brain metastasis of driver gene⁃negative were selected as the research subjects, and they were randomly divided into study group or control group, with 70 cases in each group. Patients in the control group received simple brain radiotherapy (stereotactic radiotherapy/whole brain radiotherapy), based on which the study group received combined application of pembrolizumab for treatment. The clinical efficacy, progression⁃free survival, total survival, and the occurrence of adverse reactions were compared between patients of the two groups. Results The study group exhibited superior clinical efficacy, higher remission rate and control rate, longer progression⁃free survival and total survival, lower incidence rate of anorexia, decreased incidence rates of rash/pruritus, and neutrophils as compared with the control group (P<0.05). Conclusion On the basis of radiotherapy, jointly applying pembrolizumab to the treatment of patients with non⁃small cell lung cancer with brain metastasis of driver gene⁃negative can improve therapeutic effect, prolong patients' survival, exerting relatively high safety.

无